Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
News
FDA Approves the First-in-Class Bispecific Antibody for Treatment of Follicular Lymphoma
“This new treatment has the potential to help patients with this hard-to-treat cancer achieve remission,” says LLS Chief Scientific Officer Dr. Lee Gr…
Patient Education Webcasts
LLS Fireside Chats for Parents and Caregivers of Young Patients
Professional Education Webcasts
A Panel Discussion on Transitioning Your Student Back to School: Practical Tips and Advice
Watch this informative panel discussion of school personnel for practical tips on supporting a student attending school during or after cancer treatme…
Professional Education Webcasts
Explaining Cancer to Students: A Classroom Presentation
This classroom presentation demonstrates how to talk to children about their classmate with cancer, including understanding key words, answering commo…
Patient Education Webcasts
COVID Updates: Where We Are and Where We Go From Here
Research
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Planegg/Munich, Germany, December 11, 2022 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced results from analyses of the ongoing MANIFEST study,…
Research
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at ASH Annual Meeting
SAN DIEGO, Dec. 10, 2022 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precis…
Research
Affimed Provides Updated Clinical Data from Phase 1/2 Study from AFM13 Precomplexed Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Heidelberg, Germany, December 10, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed…
Research
Deepening Response of Bexmarilimab in Combination with SoC in Hematological Malignancies: BEXMAB Study Update
TURKU, FINLAND / BOSTON, MA - December 5, 2022 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company …
News
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
Research
ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
Marseille, France, November 11, 2022 – ImCheck Therapeutics presented today the first patient data from EVICTION-2, a Phase I/II clinical trial evalua…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
